Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)

BACKGROUND: Paclitaxel in combination with ramucirumab is the standard of care second-line therapy in gastro-esophageal adenocarcinoma (GEA). As the number of taxane pretreated patients in the perioperative or first-line setting is increasing, it is unknown whether these patients benefit from re-app...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzen, Sylvie, Schwarz, Alix, Pauligk, Claudia, Goekkurt, Eray, Stocker, Gertraud, Knorrenschild, Jorge Riera, Illerhaus, Gerald, Dechow, Tobias, Moehler, Markus, Moulin, Jean-Charles, Pink, Daniel, Stahl, Michael, Schaaf, Marina, Goetze, Thorsten Oliver, Al-Batran, Salah-Eddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278289/
https://www.ncbi.nlm.nih.gov/pubmed/37337155
http://dx.doi.org/10.1186/s12885-023-11004-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278289/
https://www.ncbi.nlm.nih.gov/pubmed/37337155
http://dx.doi.org/10.1186/s12885-023-11004-z

Ejemplares similares